Business
Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several
About this update from Sangamo Therapeutics, Inc.
[{"type":"text","content":" BRISBANE, Calif.--(BUSINESS WIRE)--\nSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 12th to May 15th, 2020, in a virtual format.\n\n\n“Sangamo’s abstracts at ASGCT include work from our in vivo genome transcriptional regulation programs in CNS diseases, where we aim to modulate the expression of key genes involved in Prion and Parkinson’s diseases for therapeutic effect, as well as other abstracts detailing our engineered AAV directed evolution platform and ongoing improvements to our ZFP genome editing technology that we believe will enable us to remain at the forefront of genomic medicine research and discovery,” said Adrian Woolfson, BM., B.Ch., Ph.D., Head of Research and Development at Sangamo. “Sangamo’s significant presence at ASGCT this year, with presentations showcasing our diverse and proprietary suite of genome engineering technologies across a broad range of therapeutic areas, demonstrates the generality, optionality and compelling nature of our therapeutic pipeline.”\n\n\nASGCT Annual Meeting Presentations & Invited Sessions\n\n\n\nEngineering and Evaluation of Novel AAV Serotypes for Gene Delivery to the Central Nervous System – Abstract #23\nOral Presentation – Tuesday, May 12; 10:30AM ET\n\n\nEngineered Zinc Finger Protein Transcription Factors Efficiently and Specifically Reduce Mouse and Human Prion Expression – Abstract #296\nPoster Presentation – Tuesday, May 12; 5:30PM ET\n\n\nNovel Therapeutic Approach for Parkinson’s Disease: Engineered Zinc Finger Protein Transcription Factors Efficiently and Specifically Reduce Alpha-Synuclein Expression – Abstract #711\nPoster Presentation – Wednesday, May 13; 5:30PM ET\n\n\nEngineered nuclease off-target assay with improved sensitivity – Abstract #656\nPoster Presentation – Wednesday, May 13, 5:30PM ET\n\n\nAn Expanded Repertoire of ZFN Architectures for High-Precision Therapeutic Genome Engineering – Abstract#1048\nPoster Presentation – Thursday, May 14; 5:30PM ET\n\n\nOpportunities and Challenges of Global Clinical Trials\nInvited Talk – Monday, May 11; 8:30AM ET\n\n\n\nAn additional abstract of Sangamo’s legacy HIV research, “Results of Four Clinical Trials using Autologous T-C...